OraSure (OSUR) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	5-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	1116463
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		56,417,001

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
CURRENT ASSETS:
Cash	$85,547	$92,867
Short-term investments	3,942	5,000
Accounts receivable, net of allowance for doubtful accounts of $543 and $533	16,367	16,138
Inventories	15,619	15,763
Prepaid expenses	1,559	1,140
Other current assets	149	306
Total current assets	123,183	131,214
PROPERTY AND EQUIPMENT, net	17,645	17,934
INTANGIBLE ASSETS, net	15,581	17,505
GOODWILL	19,913	21,734
OTHER ASSETS	1,320	1,246
TOTAL ASSETS	177,642	189,633
CURRENT LIABILITIES:
Accounts payable	5,037	7,148
Deferred revenue	5,492	8,043
Deferred income taxes	128	139
Accrued expenses	6,877	11,132
Total current liabilities	17,534	26,462
OTHER LIABILITIES	1,311	1,234
DEFERRED INCOME TAXES	2,970	3,236
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 56,416 and 56,187 shares issued and outstanding	0	0
Additional paid-in capital	345,718	344,894
Accumulated other comprehensive loss	-11,659	-7,848
Accumulated deficit	-178,232	-178,345
Total stockholders' equity	155,827	158,701
Total liabilities and stockholders' equity	$177,642	$189,633

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$543	$533
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	56,416,000	56,187,000
Common stock, shares outstanding	56,416,000	56,187,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
NET REVENUES:
Product	$23,765	$23,537
Other	3,323
Total revenue	27,088	23,537
COST OF PRODUCTS SOLD	10,090	9,610
Gross profit	16,998	13,927
OPERATING EXPENSES:
Research and development	3,440	2,481
Sales and marketing	7,884	11,340
General and administrative	5,965	5,724
Total operating expenses	17,289	19,545
Operating loss	-291	-5,618
OTHER INCOME	409	118
Income (loss) before income taxes	118	-5,500
INCOME TAXES	5	131
NET INCOME (LOSS)	$113	($5,631)
EARNINGS (LOSS) PER SHARE:
BASIC	$0	($0.10)
DILUTED	$0	($0.10)
SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:
BASIC	56,343	55,762
DILUTED	57,173	55,762

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$113	($5,631)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	-3,811	-1,778
Other comprehensive loss	-3,811	-1,778
COMPREHENSIVE LOSS	($3,698)	($7,409)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES:
NET INCOME (LOSS)	$113	($5,631)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation	1,475	1,406
Depreciation and amortization	1,409	1,539
Unrealized foreign currency gain	-71
Deferred income taxes	5	131
Changes in assets and liabilities
Accounts receivable	-552	-402
Inventories	57	-586
Prepaid expenses and other assets	-290	-280
Accounts payable	-2,062	-683
Deferred revenue	-2,542	-153
Accrued expenses and other liabilities	-4,133	-3,009
Net cash used in operating activities	-6,591	-7,668
INVESTING ACTIVITIES:
Purchases of short term investments	-3,961
Proceeds from maturities of short term investments	5,000
Purchases of property and equipment	-437	-647
Net cash provided by (used in) investing activities	602	-647
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	121	93
Repurchase of common stock	-772	-521
Net cash used in financing activities	-651	-428
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	-680	-255
NET DECREASE IN CASH	-7,320	-8,998
CASH, BEGINNING OF PERIOD	92,867	93,191
CASH, END OF PERIOD	85,547	84,193
Cash paid for:
Income taxes	$81	$40

The_Company

The Company	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1	The Company
	We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care, tests that are processed in a laboratory, and a rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2	Summary of Significant Accounting Policies
	Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
	The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results of operations expected for the full year.
	Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
	Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.
	Our available-for-sale securities as of March 31, 2015 and December 31, 2014 consisted of guaranteed investment certificates with amortized cost and fair values of $3,942 and $5,000, respectively.
	Fair Value of Financial Instruments. As of March 31, 2015 and December 31, 2014, the carrying values of cash, short-term investments, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.
	Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2015 and December 31, 2014 was $1,314 and $1,234, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.
	All of our available-for-sale securities are measured as Level 1 instruments as of March 31, 2015 and December 31, 2014.
	Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:
			March 31, 2015				December 31, 2014
	Raw materials		$	8,256			$	8,539
	Work in process			764				898
	Finished goods			6,599				6,326
			$	15,619			$	15,763
	Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2015 and December 31, 2014 was $32,049 and $31,416, respectively.
	Intangible Assets. Intangible assets consist of the following:
					March 31, 2015
			Amortization		Gross				Accumulated			Net
			Period (Years)						Amortization
	Customer list		10		$	9,876			$	(3,449	)	$	6,427
	Patents and product rights		10-Mar			10,449				(8,069	)		2,380
	Acquired technology		7			7,671				(3,769	)		3,902
	Tradename		15			3,786				(914	)		2,872
					$	31,782			$	(16,201	)	$	15,581
					December 31, 2014
			Amortization		Gross				Accumulated			Net
			Period (Years)						Amortization
	Customer list		10		$	10,779			$	(3,508	)	$	7,271
	Patents and product rights		10-Mar			10,449				(7,957	)		2,492
	Acquired technology		7			8,372				(3,833	)		4,539
	Tradename		15			4,132				(929	)		3,203
					$	33,732			$	(16,227	)	$	17,505
	Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.
	We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2015, we believe no indicators of impairment exist.
	The change in goodwill from $21,734 as of December 31, 2014 to $19,913 as of March 31, 2015 is a result of foreign currency translation.
	Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information, and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as other revenue in our statements of operations.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
	On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets covered by this agreement.
	Pursuant to the Co-Promotion Agreement, we have granted exclusive co-promotion rights for the OraQuick® HCV test in certain markets to AbbVie and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV test in certain market segments.
	In exchange for these exclusive rights and other services, we are eligible to receive up to $75,000 in aggregate payments over the term of the agreement, which runs through December 31, 2019. We plan to recognize the payments ratably on a monthly basis over the term of the agreement. In addition, if certain performance-based milestones are achieved, we may be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the term of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Amounts related to this agreement will be recorded as other revenue in our statements of operations.
	Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2015 and December 31, 2014, the reserve for sales returns and allowances was $387 and $437, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
	Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2015 and December 31, 2014 includes customer prepayments of $1,386 and $613, respectively. Deferred revenue as of March 31, 2015 and December 31, 2014 also includes $4,106 and $7,430 from AbbVie, respectively, which represents the $15,000 payment received in July 2014 under the terms of our HCV co-promotion agreement with AbbVie, less amounts recognized ratably in revenue.
	Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 13% of our accounts receivable balance as of March 31, 2015. We had no significant concentrations (greater than 10%) in accounts receivable as of December 31, 2014. AbbVie accounted for approximately 12% of our net revenues for the three months ended March 31, 2015. We had no significant concentrations (greater than 10%) in net revenues for the three months ended March 31, 2014.
	We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
	Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.
	The computations of basic and diluted earnings (loss) per share are as follows:
			Three Months
			Ended March 31,
			2015				2014
	Net income (loss)		$	113			$	(5,631	)
	Weighted average shares of common stock outstanding:
	Basic			56,343				55,762
	Dilutive effect of stock options and restricted stock			830				—
	Diluted			57,173				55,762
	Earnings (loss) per share:
	Basic		$	0			$	(0.10	)
	Diluted		$	0			$	(0.10	)
For the three-month periods ended March 31, 2015 and 2014, outstanding common stock options and unvested restricted stock, representing 2,702 and 3,698 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive.
Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $3,811 and $1,778 currency translation adjustments recorded in the first three months of 2015 and 2014, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.
Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. However, the FASB has proposed a one-year deferral of the effective date of this standard. We are still evaluating the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders' Equity	3	Stockholders’ Equity
	Stock-Based Awards
	We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or vesting of restricted stock, we issue new shares rather than purchase shares on the open market.
	Total compensation cost related to stock options for the three months ended March 31, 2015 and 2014 was $822 and $719, respectively. Net cash proceeds from the exercise of stock options were $121 and $93 for the three months ended March 31, 2015 and 2014, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.
	The following table summarizes the stock option activity for the three months ended March 31, 2015:
			Options
	Outstanding on January 1, 2015			5,740
	Granted			767
	Exercised			(74	)
	Expired			(35	)
	Forfeited			(29	)
	Outstanding on March 31, 2015			6,369
	Compensation cost of $653 and $687 related to restricted shares was recognized during the three months ended March 31, 2015 and 2014, respectively. In connection with the vesting of restricted shares and exercise of stock options during the three months ended March 31, 2015 and 2014, we purchased and immediately retired 112 and 89 shares with aggregate values of $772 and $521, respectively, in satisfaction of minimum tax withholding and exercise obligations.
	The following table summarizes restricted stock award activity for the three months ended March 31, 2015:
			Shares
	Issued and unvested, January 1, 2015			707
	Granted			265
	Vested			(267	)
	Forfeited			(9	)
	Issued and unvested, March 31, 2015			696

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	4	Accrued Expenses
			March 31, 2015		December 31, 2014
	Payroll and related benefits		$	2,902	$	6,620
	Royalties			1,703		2,285
	Professional fees			758		480
	Other			1,514		1,747
			$	6,877	$	11,132

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	5	Income Taxes
	During the three months ended March 31, 2015 and 2014, we recorded foreign deferred tax expense of $5 and $131, respectively.
	Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2015 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.
	In 2008, we established a full valuation allowance against our U.S. net deferred tax asset. Management believes the full valuation allowance is still appropriate as of March 31, 2015 and December 31, 2014 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three month periods ended March 31, 2015 and 2014.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6	Commitments and Contingencies
	From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

Business_Segment_Information

Business Segment Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Business Segment Information	7	Business Segment Information
	We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including royalties from the grant of license rights, exclusivity payments for co-promotion rights, and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.
	We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.
	The following table summarizes operating segment information for the three months ended March 31, 2015 and 2014 and asset information as of March 31, 2015 and December 31, 2014:
			Three Months Ended March 31,
			2015			2014
	Net revenues:
	OSUR		$	20,371		$	17,778
	DNAG			6,717			5,759
	Total		$	27,088		$	23,537
	Operating income (loss):
	OSUR		$	(1,521	)	$	(6,394	)
	DNAG			1,230			776
	Total		$	(291	)	$	(5,618	)
	Depreciation and amortization:
	OSUR		$	726		$	776
	DNAG			683			763
	Total		$	1,409		$	1,539
	Capital expenditures:
	OSUR		$	76		$	439
	DNAG			361			208
	Total		$	437		$	647
			March 31, 2015			December 31, 2014
	Total assets:
	OSUR		$	127,273		$	136,542
	DNAG			50,369			53,091
	Total		$	177,642		$	189,633
	Our products are sold principally in the United States and Europe.
	The following table represents total revenues by geographic area, based on the location of the customer:
			Three Months Ended March 31,
			2015			2014
	United States		$	20,416		$	17,406
	Europe			4,374			4,001
	Other regions			2,298			2,130
			$	27,088		$	23,537
	The following table represents total long-lived assets by geographic area:
			March 31, 2015			December 31, 2014
	United States		$	16,093		$	16,570
	Canada			1,542			1,353
	Other regions			10			11
			$	17,645		$	17,934

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
	The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results of operations expected for the full year.
Use of Estimates	Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
Short-Term Investments	Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.
	Our available-for-sale securities as of March 31, 2015 and December 31, 2014 consisted of guaranteed investment certificates with amortized cost and fair values of $3,942 and $5,000, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. As of March 31, 2015 and December 31, 2014, the carrying values of cash, short-term investments, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.
	Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2015 and December 31, 2014 was $1,314 and $1,234, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.
	All of our available-for-sale securities are measured as Level 1 instruments as of March 31, 2015 and December 31, 2014.
Inventories	Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:
		March 31, 2015				December 31, 2014
	Raw materials	$	8,256			$	8,539
	Work in process		764				898
	Finished goods		6,599				6,326
		$	15,619			$	15,763
Property and Equipment	Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2015 and December 31, 2014 was $32,049 and $31,416, respectively.
Intangible Assets	Intangible Assets. Intangible assets consist of the following:
				March 31, 2015
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	9,876			$	(3,449	)	$	6,427
	Patents and product rights	10-Mar			10,449				(8,069	)		2,380
	Acquired technology	7			7,671				(3,769	)		3,902
	Tradename	15			3,786				(914	)		2,872
				$	31,782			$	(16,201	)	$	15,581
				31-Dec-14
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	10,779			$	(3,508	)	$	7,271
	Patents and product rights	10-Mar			10,449				(7,957	)		2,492
	Acquired technology	7			8,372				(3,833	)		4,539
	Tradename	15			4,132				(929	)		3,203
				$	33,732			$	(16,227	)	$	17,505
Goodwill	Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.
	We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2015, we believe no indicators of impairment exist.
	The change in goodwill from $21,734 as of December 31, 2014 to $19,913 as of March 31, 2015 is a result of foreign currency translation.
Revenue Recognition	Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information, and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as other revenue in our statements of operations.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
	On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets covered by this agreement.
	Pursuant to the Co-Promotion Agreement, we have granted exclusive co-promotion rights for the OraQuick® HCV test in certain markets to AbbVie and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV test in certain market segments.
	In exchange for these exclusive rights and other services, we are eligible to receive up to $75,000 in aggregate payments over the term of the agreement, which runs through December 31, 2019. We plan to recognize the payments ratably on a monthly basis over the term of the agreement. In addition, if certain performance-based milestones are achieved, we may be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the term of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Amounts related to this agreement will be recorded as other revenue in our statements of operations.
Customer Sales Returns and Allowances	Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2015 and December 31, 2014, the reserve for sales returns and allowances was $387 and $437, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
Deferred Revenue	Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2015 and December 31, 2014 includes customer prepayments of $1,386 and $613, respectively. Deferred revenue as of March 31, 2015 and December 31, 2014 also includes $4,106 and $7,430 from AbbVie, respectively, which represents the $15,000 payment received in July 2014 under the terms of our HCV co-promotion agreement with AbbVie, less amounts recognized ratably in revenue.
Customer and Vendor Concentrations	Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 13% of our accounts receivable balance as of March 31, 2015. We had no significant concentrations (greater than 10%) in accounts receivable as of December 31, 2014. AbbVie accounted for approximately 12% of our net revenues for the three months ended March 31, 2015. We had no significant concentrations (greater than 10%) in net revenues for the three months ended March 31, 2014.
	We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Earnings (Loss) Per Share	Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.
	The computations of basic and diluted earnings (loss) per share are as follows:
		Three Months
		Ended March 31,
		2015				2014
	Net income (loss)	$	113			$	(5,631	)
	Weighted average shares of common stock outstanding:
	Basic		56,343				55,762
	Dilutive effect of stock options and restricted stock		830				—
	Diluted		57,173				55,762
	Earnings (loss) per share:
	Basic	$	0			$	(0.10	)
	Diluted	$	0			$	(0.10	)
	For the three-month periods ended March 31, 2015 and 2014, outstanding common stock options and unvested restricted stock, representing 2,702 and 3,698 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive.
Foreign Currency Translation	Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
	Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
	We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $3,811 and $1,778 currency translation adjustments recorded in the first three months of 2015 and 2014, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.
Recent Accounting Pronouncements	Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. However, the FASB has proposed a one-year deferral of the effective date of this standard. We are still evaluating the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Inventories	Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:
		March 31, 2015				December 31, 2014
	Raw materials	$	8,256			$	8,539
	Work in process		764				898
	Finished goods		6,599				6,326
		$	15,619			$	15,763
Summary of Intangible Assets	Intangible assets consist of the following:
				March 31, 2015
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	9,876			$	(3,449	)	$	6,427
	Patents and product rights	10-Mar			10,449				(8,069	)		2,380
	Acquired technology	7			7,671				(3,769	)		3,902
	Tradename	15			3,786				(914	)		2,872
				$	31,782			$	(16,201	)	$	15,581
				December 31, 2014
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	10,779			$	(3,508	)	$	7,271
	Patents and product rights	10-Mar			10,449				(7,957	)		2,492
	Acquired technology	7			8,372				(3,833	)		4,539
	Tradename	15			4,132				(929	)		3,203
				$	33,732			$	(16,227	)	$	17,505
Computations of Basic and Diluted Earnings (Loss) per Share	The computations of basic and diluted earnings (loss) per share are as follows:
		Three Months
		Ended March 31,
		2015				2014
	Net income (loss)	$	113			$	(5,631	)
	Weighted average shares of common stock outstanding:
	Basic		56,343				55,762
	Dilutive effect of stock options and restricted stock		830				—
	Diluted		57,173				55,762
	Earnings (loss) per share:
	Basic	$	0			$	(0.10	)
	Diluted	$	0			$	(0.10	)

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Summary of Company's Stock Option Activity	The following table summarizes the stock option activity for the three months ended March 31, 2015:
		Options
	Outstanding on January 1, 2015		5,740
	Granted		767
	Exercised		(74	)
	Expired		(35	)
	Forfeited		(29	)
	Outstanding on March 31, 2015		6,369
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the three months ended March 31, 2015:
		Shares
	Issued and unvested, January 1, 2015		707
	Granted		265
	Vested		(267	)
	Forfeited		(9	)
	Issued and unvested, March 31, 2015		696

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses
		March 31, 2015		December 31, 2014
	Payroll and related benefits	$	2,902	$	6,620
	Royalties		1,703		2,285
	Professional fees		758		480
	Other		1,514		1,747
		$	6,877	$	11,132

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Summary of Operating Segment and Asset Information	The following table summarizes operating segment information for the three months ended March 31, 2015 and 2014 and asset information as of March 31, 2015 and December 31, 2014:
		Three Months Ended March 31,
		2015			2014
	Net revenues:
	OSUR	$	20,371		$	17,778
	DNAG		6,717			5,759
	Total	$	27,088		$	23,537
	Operating income (loss):
	OSUR	$	(1,521	)	$	(6,394	)
	DNAG		1,230			776
	Total	$	(291	)	$	(5,618	)
	Depreciation and amortization:
	OSUR	$	726		$	776
	DNAG		683			763
	Total	$	1,409		$	1,539
	Capital expenditures:
	OSUR	$	76		$	439
	DNAG		361			208
	Total	$	437		$	647
		March 31, 2015			December 31, 2014
	Total assets:
	OSUR	$	127,273		$	136,542
	DNAG		50,369			53,091
	Total	$	177,642		$	189,633
Presentation of Total Revenues and Long-Lived Assets by Geographic Area	The following table represents total revenues by geographic area, based on the location of the customer:
		Three Months Ended March 31,
		2015			2014
	United States	$	20,416		$	17,406
	Europe		4,374			4,001
	Other regions		2,298			2,130
		$	27,088		$	23,537
	The following table represents total long-lived assets by geographic area:
		March 31, 2015			December 31, 2014
	United States	$	16,093		$	16,570
	Canada		1,542			1,353
	Other regions		10			11
		$	17,645		$	17,934

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jul. 31, 2014
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, fair values	$3,942		$5,000
Fair value of plan assets	1,314		1,234
Accumulated depreciation of property and equipment	32,049		31,416
Amount of goodwill at period end	19,913		21,734
Expiration date of rights agreement	31-Dec-19
Revenue recognition, milestone method description	We may be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the term of the agreement. The first performance-based milestone period ends on December 31, 2015.
Reserve for sales return and allowances	387		437
Deferred revenue	5,492		8,043
Concentration rate of accounts receivable		10.00%	10.00%
Number of anti-dilutive securities excluded from EPS computation	2,702	3,698
Accumulated foreign currency adjustments included in other comprehensive loss amounted	3,811	1,778
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	1,386		613
AbbVie [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	4,106		7,430
Deferred revenue payment received				15,000
Guaranteed Investment Certificates [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Available-for-sale securities, amortized cost	3,942		3,942
Available-for-sale securities, fair values	5,000		5,000
Reckitt Benckiser [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of customers, accounted for significant concentrations	1
Reckitt Benckiser [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration rate of accounts receivable	13.00%
AbbVie [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration rate of accounts receivable	12.00%
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Payments received for sale of exclusive rights	75,000
Additional annual payments to be received for sale of exclusive rights	55,500
Maximum [Member] | Building [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	40 years
Maximum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional annual payments to be received for sale of exclusive rights	$3,500
Minimum [Member] | Building [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member] | Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] | Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] | Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products	2

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory, Net [Abstract]
Raw materials	$8,256	$8,539
Work in process	764	898
Finished goods	6,599	6,326
Inventories	$15,619	$15,763

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross	$31,782	$33,732
Accumulated Amortization	-16,201	-16,227
Net	15,581	17,505
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	9,876	10,779
Accumulated Amortization	-3,449	-3,508
Net	6,427	7,271
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	10,449	10,449
Accumulated Amortization	-8,069	-7,957
Net	2,380	2,492
Patents and Product Rights [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	3 years	3 years
Patents and Product Rights [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Gross	7,671	8,372
Accumulated Amortization	-3,769	-3,833
Net	3,902	4,539
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years
Gross	3,786	4,132
Accumulated Amortization	-914	-929
Net	$2,872	$3,203

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$113	($5,631)
Weighted average shares of common stock outstanding:
BASIC	56,343	55,762
Dilutive effect of stock options and restricted stock	830
Diluted	57,173	55,762
BASIC	$0	($0.10)
DILUTED	$0	($0.10)

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended
Share data in Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$1,475,000	$1,406,000
Net cash proceeds from the exercise of stock options	121,000	93,000
Income tax benefit realized from stock option exercises during period	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	822,000	719,000
Net cash proceeds from the exercise of stock options	121,000	93,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	653,000	687,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations	112	89
Restricted shares of common stock and stock options, aggregate values	$772,000	$521,000

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance	5,740
Options, Granted	767
Options, Exercised	-74
Options, Expired	-35
Options, Forfeited	-29
Options, Outstanding, Ending Balance	6,369

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Equity [Abstract]
Shares, Issued and unvested, Beginning Balance	707
Shares, Granted	265
Shares, Vested	-267
Shares, Forfeited	-9
Shares, Issued and unvested, Ending Balance	696

Accrued_Expenses_Schedule_of_A

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$2,902	$6,620
Royalties	1,703	2,285
Professional fees	758	480
Other	1,514	1,747
Accrued Expenses, Total	$6,877	$11,132

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Foreign deferred tax expense	$5,000	$131,000
U.S. federal income tax benefits	0	0
U.S. state income tax benefits	$0	$0

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business_Segment_Information_S

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Net revenues	$27,088	$23,537
Operating income (loss)	-291	-5,618
Depreciation and amortization	1,409	1,539
Capital expenditures	437	647
Total assets	177,642		189,633
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	20,371	17,778
Operating income (loss)	-1,521	-6,394
Depreciation and amortization	726	776
Capital expenditures	76	439
Total assets	127,273		136,542
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	6,717	5,759
Operating income (loss)	1,230	776
Depreciation and amortization	683	763
Capital expenditures	361	208
Total assets	$50,369		$53,091

Business_Segment_Information_P

Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$27,088	$23,537
Long-lived assets	17,645		17,934
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	20,416	17,406
Long-lived assets	16,093		16,570
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	4,374	4,001
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	2,298	2,130
Long-lived assets	10		11
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$1,542		$1,353